{"filings":[{"id":2216762,"accession_number":"0001104659-26-094862","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2026-08-12T20:05:37+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q2 revenue up 23% to $18.5M; net loss narrows to $0.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $18.5M for Q2 2026, +23% from $15.0M in Q2 2025; Emrosi sales $8.1M.","GAAP net loss narrowed to $0.3M ($0.01/sh) from $3.8M ($0.16/sh) year ago.","Non-GAAP EBITDA and Adjusted EBITDA positive for both three and six months ended June 30, 2026.","Cash $25.6M at June 30, 2026 vs $24.1M at Dec 31, 2025; SG&A down $1.0M to $10.9M.","Emrosi total prescriptions ~36,000 in Q2 2026, up from ~30,000 in Q1 and ~27,000 in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1285436,"accession_number":"0001104659-26-077888","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2026-06-26T00:01:02+00:00","items":["5.07"],"status":"ready","headline":"Journey Medical shareholders elect all six directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Six directors elected: Rosenwald, Maraoui, Herskowitz, Smith, Toledano, Pearce – all with >96% 'For' votes among votes cast.","KPMG ratified as independent auditor for FY 2026: 39.4M for, 50k against, 202k abstain.","81% of eligible shares represented in person or by proxy, constituting a quorum.","Broker non-votes of 6.5M shares on director election due to discretionary voting rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68002,"accession_number":"0001104659-26-060232","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2026-05-13T20:06:07+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q1 revenue $16M (+21% YoY); Emrosi sales triple to $6.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $16.0M, +21% YoY vs $13.1M; Emrosi revenue $6.3M vs $2.1M in Q1 2025.","Net loss narrowed to $2.2M ($0.08 loss per share) from $4.1M ($0.18 loss per share) YoY.","Adjusted EBITDA turned positive at $0.6M ($0.02 per share) vs negative $0.9M in Q1 2025.","Cash increased to $27M; gross margin 61% impacted by $1.3M non-cash API write-down.","SG&A down $0.5M to $10.1M due to lower Emrosi launch costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96400,"accession_number":"0001104659-26-046158","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Journey Medical expands Emrosi payer coverage to ~85% of US commercial lives after third GPO contract","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Secured contract with third major GPO, expanding Emrosi commercial access from ~100M to >150M lives as of April 1, 2026.","Approximately 85% of all US commercial lives now have access to Emrosi for treatment of inflammatory rosacea lesions.","CEO cites milestone for Emrosi launch; expects less reliance on copay bridging and improved profitability as formulary adoption grows.","Focus remains on converting access into coverage through health plan formulary adoption throughout 2026 and beyond."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110277,"accession_number":"0001104659-26-034506","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical FY2025 revenue $61.9M (+10% YoY); net loss narrows to $11.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Emrosi launch contributed $14.7M net revenue; ~53,000 prescriptions filled in FY2025.","Gross margin improved to 66.2% from 62.8%, driven by higher-margin Emrosi and Qbrexza.","Adjusted EBITDA positive $2.9M ($0.12 per diluted share) vs $0.8M in prior year.","SG&A rose 10% to $44.4M due to Emrosi commercialization costs.","Accutane revenue declined $6.5M amid competitive pressures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126859,"accession_number":"0001104659-25-110344","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q3 2025 revenue $17.6M (+21% YoY); Emrosi sales $4.9M, prescriptions up 146%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net revenues $17.6M, up 21% YoY from $14.6M; driven by Emrosi launch.","Emrosi net sales $4.9M; prescriptions increased 146% sequentially vs Q2 2025.","Net loss narrowed to $2.3M ($0.09/sh) from $2.4M ($0.12/sh) in Q3 2024.","Adjusted EBITDA improved to positive $1.7M vs $0.3M in prior-year quarter.","Gross margin 67.4% vs 69.4% in Q3 2024 (prior year benefited from one-time adjustments)."],"consensus_eps_estimate":-0.0485,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":45779000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143656,"accession_number":"0001104659-25-093891","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Journey Medical extends term loan maturity to June 2028 and lowers revenue threshold for deferred repayment to $60M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity of $25M Term Loan extended from Dec 27, 2027 to June 27, 2028.","If trailing 12-month revenue > $60M as of Dec 31, 2025 (down from $70M), principal repayment deferred to Feb 2027.","Without revenue trigger, quarterly repayment begins Feb 2026 at 7.5% of principal.","With revenue trigger, quarterly repayment at 10% starting Feb 2027 (down from 15%).","All $25M drawn; agreement amended with SWK Funding LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143655,"accession_number":"0001104659-25-084879","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Journey Medical signs new ATM agreement to sell up to 3.75M common shares, ends prior B. Riley facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Sales Agreement with B. Riley and Lake Street allows sale of up to 3,750,000 shares of common stock at the market.","Agents will receive a commission of 3.0% of gross proceeds from sales under the new agreement.","Prior Sales Agreement with B. Riley terminated effective August 28, 2025; 4,121,318 shares sold under it since December 2022.","Company is not obligated to make any sales; offering terminates upon sale of all shares or agreement termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143654,"accession_number":"0001104659-25-076825","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q2 revenue $15.0M; Emrosi sales $2.8M in first full quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.8M ($0.16 EPS) vs $3.4M loss ($0.17 EPS) in Q2 2024.","Total net product revenue $15.0M, up slightly from $14.9M year-over-year.","Gross margin improved to 67% from 61% due to favorable product mix and lower COGS.","SG&A expenses rose to $11.9M from $10.3M, driven by Emrosi launch costs.","Adjusted EBITDA loss of $0.5M vs positive $0.3M in prior year period."],"consensus_eps_estimate":-0.1071,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":28148000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143653,"accession_number":"0001104659-25-067767","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Journey Medical expands Emrosi payer coverage to 65% of commercial lives from 29% in May 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Emrosi now has pharmacy benefit coverage for 65% of 187 million U.S. commercial lives, up from 29% in May 2025.","Expanded coverage expected to drive further growth in total prescription demand for rosacea treatment.","CEO cites targeted contracting strategy, increasing prescription demand, and superior clinical data as drivers.","Emrosi is available by prescription at specialty pharmacy chains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161869,"accession_number":"0001104659-25-063032","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Journey Medical stockholders approve officer exculpation charter amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended certificate of incorporation effective June 24, 2025, adding officer exculpation.","Six directors elected: Rosenwald, Maraoui, Herskowitz, Smith, Toledano, Pearce; all received >25.4M votes for.","KPMG LLP ratified as independent auditor for FY 2025 with 32.5M votes for, 10,433 against.","Charter amendment approved with 25.4M for, 799K against, 6.3M broker non-votes.","Quorum of 85% of eligible shares represented; 19.7M common and 6M Class A shares voted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161868,"accession_number":"0001104659-25-061956","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Journey Medical to join Russell 2000 and Russell 3000 indexes effective June 27","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Joins Russell 2000 and Russell 3000 indexes after market close on June 27, 2025.","Inclusion from 2025 annual Russell reconstitution; expected to boost investor visibility.","CEO states Emrosi launch off to strong start; believes 2025 could be transformational.","Over $10.6 trillion in assets benchmarked to Russell U.S. indexes globally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161867,"accession_number":"0001104659-25-048502","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical reports Q1 net loss narrows to $4.1M; Emrosi launch underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.1M ($0.18/sh) vs $10.4M loss ($0.53/sh) in Q1 2024.","Revenue $13.1M, flat YoY; includes $2.1M from Emrosi launch.","Gross margin improved to 64% from 54% YoY; R&D costs nil vs $7.9M.","Cash $21.1M at March 31, 2025 (vs $20.3M at Dec 31, 2024).","Emrosi commercial launch started April 7; Phase 3 results published in JAMA Dermatology."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":13139000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161866,"accession_number":"0001104659-25-031463","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Journey Medical appoints Ramsey Alloush as COO; remains General Counsel","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ramsey Alloush, previously General Counsel, appointed COO effective April 1, 2025.","He continues as General Counsel; base salary $392,945 with 50% bonus target.","Alloush led the Company's IPO, major transactions, and Hatch-Waxman litigations.","Press release cites imminent Emrosi launch and commitment to operational excellence.","No family relationships or material transactions with directors/officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179926,"accession_number":"0001104659-25-028226","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical reports FY2024 revenue $56.1M, net loss $14.7M; Emrosi launch underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $56.1M, down 29% YoY; product revenue net $55.1M (-8%) due to higher rebates and lower legacy volumes.","Net loss $14.7M ($0.72/sh) vs $3.9M loss prior year; adjusted EBITDA $0.8M vs $15.6M.","FDA approved Emrosi (minocycline) for rosacea Nov 2024; distribution started, first prescriptions filled, full promo expected April 2025.","Met all 2024 financial guidance: product revenue $55-60M, SG&A $39-42M, R&D $9-10M.","Non-GAAP adjusted EBITDA per share $0.04 basic, $0.03 diluted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179925,"accession_number":"0001104659-25-026878","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Journey Medical launches Emrosi for rosacea; first prescriptions filled","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Emrosi (40 mg minocycline HCl modified-release) launched for inflammatory lesions of rosacea in adults.","First prescriptions filled; initial distribution to specialty pharmacy chains ongoing.","FDA approval was obtained in November 2024; Emrosi is the lowest-dose oral minocycline for rosacea.","Clinical trials showed significantly superior outcomes vs. Oracea and placebo with comparable safety."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179924,"accession_number":"0001104659-25-009641","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Journey Medical expects $20.3M cash; reaffirms FY2024 revenue guidance $55-60M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Cash and cash equivalents expected to be $20.3 million as of December 31, 2024.","Reaffirms FY2024 guidance: net product revenue $55-60M, SG&A $39-42M, R&D $8-10M.","Hosts Feb 5, 2025 conference call to update commercial launch plan for Emrosi (minocycline HCl ER 40 mg).","Investor presentation (Exhibit 99.1) attached but specific slide content not disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":56134000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196727,"accession_number":"0001104659-24-116762","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q3 2024 revenue $14.6M, net loss $2.4M; Emrosi FDA approved for rosacea","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA approved Emrosi (minocycline HCl ER 40 mg) for rosacea in adults; launch expected late Q1/early Q2 2025.","Net product revenues $14.6M, down 4% YoY; Qbrexza sales up 29% to $7.6M.","Net loss $2.4M ($0.12/sh) vs net income $16.8M ($0.91/sh) in Q3 2023 (included $19M license payment).","Adjusted EBITDA $0.3M ($0.01/sh) vs $20.8M ($1.13/sh) in Q3 2023.","Gross margin improved to 63.9% from 57.9% due to lower inventory charges and royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":42514000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196726,"accession_number":"0001104659-24-113659","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"FDA approves Emrosi for rosacea; Q3 prelim revenue $14.6M, net loss $2.4M; FY guidance unchanged","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Emrosi (minocycline HCl ER 40 mg) for inflammatory lesions of rosacea in adults; initial supply expected late Q1 or early Q2 2025.","Q3 2024 prelim net product revenue $14.6M (vs $15.3M YoY); net loss $2.4M (vs $16.8M net income Q3 2023 which had $19.3M license payment).","Nine-month 2024 net product revenue $42.5M (vs $44.4M); net loss $16.2M (vs $1.7M); R&D $9.6M includes $4.1M FDA fee and $3.0M milestone to DRL.","FY 2024 guidance unchanged: net revenue $55-60M, SG&A $39-42M, R&D $9-10M.","Approval triggered $15M milestone to Dr. Reddy's; mandatory $5M draw under SWK Credit; expects $4.4M recovery from 2021 cyber incident in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213022,"accession_number":"0001104659-24-088345","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q2 net product revenue $14.9M, net loss narrows to $3.4M; DFD-29 PDUFA Nov 4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue $14.9M, down 12% YoY but up 14% sequentially from Q1 2024.","Net loss reduced to $3.4M ($0.17/sh) from $8.4M ($0.46/sh) in Q2 2023.","Adjusted EBITDA positive $0.3M vs negative $0.6M in prior-year quarter.","DFD-29 NDA for rosacea under FDA review with PDUFA goal date November 4, 2024.","Appointed Joseph M. Benesch as permanent CFO and Michael C. Pearce to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":27885000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213021,"accession_number":"0001104659-24-079596","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["1.01","2.03","5.02"],"status":"ready","headline":"Journey Medical increases credit facility to $25M, appoints new director Michael C. Pearce","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Credit facility increased from $20M to $25M; additional $5M available upon FDA approval of DFD-29 by June 30, 2025.","Term loan matures Dec 27, 2027; interest = 3-month SOFR (floor 5%) + 7.75%.","Principal repayment starts Feb 2026 at 7.5% quarterly; delayed if trailing revenue >$70M as of Dec 2025.","Appointed Michael C. Pearce to Board (size now six); receives 30,000 RSUs, $50K annual RSU grant, $50K cash retainer.","Adopted non-qualified deferred compensation plan for non-employee directors and select executives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232142,"accession_number":"0001104659-24-074743","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Journey Medical shareholders approve 3M share increase and 10-year extension of 2015 stock plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved an amendment to the 2015 Stock Incentive Plan adding 3,000,000 shares, for a total of 10,642,857 shares authorized.","Plan expiration extended by 10 years to May 27, 2035.","All five director nominees re-elected; KPMG LLP ratified as auditor for 2024.","Proposals received strong support: ~95% of votes cast for plan amendment, 99.9% for auditor ratification.","The plan amendment became effective immediately upon stockholder approval on June 25, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232141,"accession_number":"0001104659-24-060513","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q1 rev $13M (+7% YoY); DFD-29 PDUFA Nov 4, 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.4M ($0.53 loss per share) vs $10.1M loss ($0.57 loss per share) in Q1 2023.","Non-GAAP Adjusted EBITDA turned positive at $11K ($0.001 per share) vs negative $5.3M prior year.","R&D expenses rose to $7.9M from $2.0M due to $4M FDA filing fee and $3M DRL milestone for DFD-29.","SG&A cut 37% to $8.4M; Qbrexza and Accutane each grew >20% YoY.","FDA accepted DFD-29 NDA for rosacea; PDUFA target action date November 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":13030000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232140,"accession_number":"0001104659-24-055725","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Journey Medical appoints Joseph Benesch as permanent CFO effective April 26","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mr. Benesch had served as interim CFO since January 2023 and as Corporate Controller since November 2021.","Compensation remains unchanged; any future changes will be determined by Board/Compensation Committee.","Benesch brings over 25 years of public/private accounting and life sciences experience, including prior CFO roles at Teligent and Torrent.","CEO Claude Maraoui cited Benesch's leadership as key for upcoming milestones, including potential DFD-29 FDA decision for rosacea."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250407,"accession_number":"0001104659-24-037318","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical reports FY2023 revenue $79.2M (+7% YoY); net loss narrows to $3.9M from $29.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $79.2M vs $73.7M in 2022; growth driven by $19.0M Maruho licensing revenue.","Net product revenues fell 16% to $59.7M due to generic competition and Ximino discontinuation.","Net loss improved to $3.9M ($0.21 loss per share) from $29.6M ($1.69 loss per share) in 2022.","Adjusted EBITDA turned positive to $15.6M ($0.85 basic EPS) from negative $7.3M in 2022.","NDA for rosacea candidate DFD-29 accepted by FDA; PDUFA goal date set for November 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250406,"accession_number":"0001104659-24-000325","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Journey Medical secures up to $20M credit facility from SWK Holdings for DFD-29 launch and general purposes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered into credit facility with SWK Funding LLC for up to $20M; initial draw of $15M on Dec 27, 2023.","Additional $5M available within 12 months subject to operational and financial milestones.","Term loan matures Dec 27, 2027; interest rate = 3-month SOFR (floor 5%) + 7.75%, quarterly payments.","Funds to support general corporate purposes and DFD-29 NDA submission and potential commercial launch.","Prepayment premium: 2% if within 1 year, 1% if between 1-2 years, 0% thereafter; exit fee of 5% of original principal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267947,"accession_number":"0001104659-23-124742","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dr. Jeffrey Paley resigns from Journey Medical Board effective Dec 7, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jeffrey Paley resigned from the Board of Directors effective December 7, 2023.","Resignation was not due to any disagreement with the Company's operations, policies, or practices.","No replacement director has been announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267946,"accession_number":"0001104659-23-115285","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical reports Q3 2023 net income of $16.8M vs loss a year ago; revenue up 114% YoY to $34.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $16.8M ($0.80 diluted) vs GAAP net loss $10.1M in Q3 2022.","Total net revenue $34.5M, +114% YoY, including $19.0M upfront from Maruho license for Qbrexza in Asia.","Adjusted EBITDA $20.8M ($0.99 diluted) vs -$4.0M in Q3 2022.","Cost reduction to cut annual SG&A >$17M, surpassing prior $12M target; Q3 SG&A fell 45% to $8.6M.","DFD-29 NDA for rosacea expected to be submitted to FDA around year-end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":63924000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285180,"accession_number":"0001104659-23-103747","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Journey Medical regains Nasdaq compliance with stockholders' equity rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Previously notified Aug 15, 2023 of non-compliance with Nasdaq minimum $2.5M stockholders' equity.","Received $19M upfront payment from license agreement on Aug 31, 2023 to address deficiency.","On Sep 20, 2023, Nasdaq Staff confirmed the company meets the Stockholders' Equity Requirement.","Company remains listed on Nasdaq Capital Market; delisting risk removed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285179,"accession_number":"0001104659-23-101975","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2023-09-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Journey Medical regains Nasdaq equity compliance after $19M Maruho license","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Previously disclosed Nasdaq Staff notified Company of non-compliance with $2.5M stockholders' equity requirement on August 15, 2023.","On August 31, 2023, entered exclusive license agreement with Maruho for Qbrexza; Maruho paid $19M.","Company now believes it satisfies Stockholders' Equity Requirement and awaits formal Nasdaq determination.","Company had deadline of September 29, 2023 to submit compliance plan if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285178,"accession_number":"0001104659-23-098505","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Journey Medical licenses Qbrexza to Maruho for Asia; $19M upfront payment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Journey receives $19M non-refundable upfront payment from Maruho within 10 days of signing.","Amendment to Japan license removes certain royalties and a $10M milestone but retains up to $45M in milestone payments.","Exclusive license covers 13 Asian markets including South Korea, Taiwan, Hong Kong, and Southeast Asian nations.","Maruho assumes Journey’s payment obligations to Dermira (Eli Lilly) for Territory sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285177,"accession_number":"0001104659-23-093537","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2023-08-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Journey Medical receives Nasdaq deficiency notice for stockholders' equity below $2.5M threshold","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Journey Medical on Aug 15, 2023 of non-compliance with Listing Rule 5550(b)(1) requiring minimum $2.5M stockholders' equity; company reported equity of $5,000 as of June 30, 2023.","Company has 45 calendar days to submit a plan to regain compliance; if accepted, Nasdaq may grant up to 180-day extension.","Company also fails alternative standards: market value of listed securities at least $35M or net income of $500K in recent years.","Trading continues on Nasdaq under symbol DERM; no immediate delisting effect but risk of suspension if compliance not regained.","Company intends to take reasonable measures but gives no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285176,"accession_number":"0001104659-23-088823","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q2 net loss $8.4M, revenue $17.2M; DFD-29 Phase 3 positive, NDA submission H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 net revenues $17.2M, down 6% YoY but up 41% QoQ; core product revenue grew 19% YoY to $15.6M (92% of total).","GAAP net loss $8.4M ($0.46/sh) vs $7.5M loss ($0.43/sh) in Q2 2022; adjusted EBITDA improved to -$0.6M from -$2.6M.","DFD-29 Phase 3 trials met co-primary and all secondary endpoints, superior to placebo and Oracea; NDA submission planned H2 2023.","Non-cash impairment of Ximino intangible asset of $3.1M; SG&A down 20% to $12.1M from cost reduction initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":29385000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285175,"accession_number":"0001104659-23-084082","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Journey Medical repays ~$10M debt to East West Bank, terminating credit agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid approximately $10 million principal plus accrued interest and fees under EWB Credit Agreement.","Repayment satisfied all outstanding debt obligations and automatically terminated the agreement.","No prepayment fees or penalties were incurred as a result of the transaction.","Company eliminates future interest payments on that debt, improving cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305037,"accession_number":"0001104659-23-074239","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Journey Medical stockholders approve 2023 ESPP, elect directors, ratify KPMG","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2023 ESPP approved with 300,000 shares reserved; employees purchase at 85% of lower of grant/purchase date FMV.","All six director nominees elected: Rosenwald, Maraoui, Herskowitz, Paley, Smith, Toledano.","KPMG ratified as independent auditor for FY23 with 19,431,599 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305036,"accession_number":"0001104659-23-063145","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"Journey Medical Q1 net loss $10.1M on revenue decline; DFD-29 topline expected June 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $12.2M, down from $20.8M YoY, due to higher gross-to-net adjustments and lower Qbrexza, Targadox, Ximino sales.","Net loss $10.1M ($0.57/share) vs. net loss $1.4M ($0.08/share) in Q1 2022; Adjusted EBITDA -$5.3M.","DFD-29 Phase 3 last patient out achieved; topline data expected June 2023; NDA filing planned H2 2023.","SG&A expenses cut to $13.3M (-10% YoY); additional annual savings >$12M vs. 2022 expected from cost reduction initiative.","Fifth Amendment to East West Bank facility: $10M term loan repaid, maturity extended to July 2024, covenants removed except minimum liquidity."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":12213000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324509,"accession_number":"0001104659-23-038309","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical reports record FY22 revenue of $73.7M (+17% YoY); net loss narrows to $29.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record total revenues of $73.7M for FY2022, up 17% from $63.1M in FY2021.","Net loss of $29.6M ($1.69/share) vs $44.0M ($4.32/share) in prior year; Adjusted EBITDA -$7.3M.","Phase 3 DFD-29 (rosacea) fully enrolled; topline data expected H1 2023; NDA filing H2 2023.","Q4 2022 revenue $16.0M, down 9% YoY due to Targadox generic competition.","SG&A expenses rose to $59.5M from $39.8M; R&D decreased to $10.9M from $16.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324508,"accession_number":"0001104659-23-005408","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2023-01-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Journey Medical CFO resigns; Corporate Controller Benesch named interim CFO effective Jan 27.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ernest De Paolantonio resigns as CFO effective Jan 27, 2023; will consult through March 31, 2023.","Joseph Benesch, Corporate Controller since Nov 2021, appointed interim CFO effective Jan 27, 2023.","Benesch has over 25 years of finance experience, is a CPA, and previously held senior roles at Teligent and Torrent.","No immediate change to Benesch's compensation; search for permanent CFO underway internally and externally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324507,"accession_number":"0001104659-23-000422","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Journey Medical enters ATM sales agreement with B. Riley for up to 4.9M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may offer and sell up to 4,900,000 shares of common stock through Agent B. Riley Securities in at-the-market offerings.","Sales require effectiveness of new S-3 registration statement filed December 30, 2022; Agent commission is 3.0% of gross proceeds.","Company is not obligated to sell any shares; agreement continues until all shares sold or terminated by either party.","Customary indemnification and expense reimbursement provided to Agent; offering may be conducted with price, time, or size limits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342377,"accession_number":"0001104659-22-117116","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q3 revenue down 18% to $16.1M; net loss $10.1M; DFD-29 Phase 3 75% enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $16.1M in Q3 2022 versus $19.6M in Q3 2021, decline due to Targadox generic competition.","Net loss $10.1M ($0.57/sh) vs $10.6M ($1.16/sh); Non-GAAP Adj EBITDA loss $4.0M vs +$1.3M.","DFD-29 Phase 3 studies 75% enrolled; top-line data expected H1 2023, NDA filing H2 2023.","Nine-month revenue up 26% to $57.7M; CEO expects record full-year 2022 revenue.","Company expects to launch another product in the upcoming months."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":57703000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359100,"accession_number":"0001104659-22-087893","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q2 net revenue up 20% to $18.3M; loss narrows to $7.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $18.3M (+20% YoY), driven by new product launches despite Targadox generic competition.","Net loss $7.5M ($0.43/sh) vs. $11.9M ($1.30/sh) in Q2 2021; Adjusted EBITDA loss $2.6M.","DFD-29 Phase 3 rosacea trials 45% enrolled; top-line data expected H1 2023, NDA in H2 2023.","Settlement with Padagis solidifies exclusivity for QBREXZA, AMZEEQ, ZILXI; supply chain delays resolved.","Tenth dermatology product launch planned in H2 2022; salesforce expanded from 42 to 84 reps."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":41587000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359099,"accession_number":"0001104659-22-081994","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2022-07-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Journey Medical grants 300k RSUs to CEO, 150k RSUs to CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Claude Maraoui received 300,000 RSUs; CFO Ernest De Paolantonio received 150,000 RSUs.","RSUs vest in four equal annual installments beginning on July 21, 2023.","Grants approved by Board on July 21, 2022 under the 2015 Stock Plan.","Unvested RSUs subject to forfeiture upon termination; full vesting upon Change of Control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377913,"accession_number":"0001104659-22-072953","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Journey Medical shareholders approve 3M-share increase to equity plan, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2015 Stock Plan increasing shares from 4,642,857 to 7,642,857 (a 64.6% increase).","All six director nominees elected: Rosenwald, Maraoui, Herskowitz, Paley, Smith, Toledano.","Ratification of KPMG as independent auditor for fiscal 2022 approved with 19,887,190 votes for.","Plan amendment became effective upon stockholder approval on June 21, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377912,"accession_number":"0001104659-22-058228","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical reports record Q1 revenue of $23.3M, up 117% YoY; net loss of $1.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record net product revenue $20.8M (+94% YoY); $2.5M milestone from Maruho for QBREXZA Japan approval.","Net loss of $1.4M ($0.08/share) vs net income $0.3M ($0.03) in Q1 2021; adjusted EBITDA $2.3M vs $1.2M.","First patient dosed in Phase 3 trial for DFD-29 for papulopustular rosacea; one additional product launch planned in H2 2022.","Expanded product portfolio with Amzeeq and Zilxi launches; now 9 marketed prescription dermatology products."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":23296000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396236,"accession_number":"0001104659-22-037193","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2022-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical reports FY2021 record revenue of $63.1M, net loss of $44.0M; DFD-29 Phase 3 underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record net product revenues of $63.1M in FY2021, up 42% from $44.5M in FY2020.","Net loss attributable to common stockholders of $44.0M ($4.32/share) vs net income of $5.3M ($0.58/share) in FY2020.","Non-GAAP adjusted EBITDA positive at $2.9M; non-GAAP net loss of $16.9M ($1.66/share).","Cash and equivalents $49.1M at Dec 31, 2021, up from $8.2M a year ago, boosted by IPO proceeds.","Dosed first patient in Phase 3 for DFD-29 for rosacea; received $10M milestone from Maruho; acquired VYNE MST franchise for $20M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396235,"accession_number":"0001104659-22-003789","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2022-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Journey Medical acquires VYNE's MST franchise for $20M upfront; credit facility expanded to $30M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired AMZEEQ, ZILXI, FCD105, and MST platform for $20M upfront plus $5M at one year; contingent milestones up to $450M.","Products generated ~$4M net sales in Q3 2021; portfolio now includes nine marketed dermatology products.","Credit facility with East West Bank expanded to $30M: $10M revolver + $20M term loan to finance acquisition and working capital.","Journey substituted as plaintiff in patent litigation against Padagis over Amzeeq; trial set for July 2023, stay until Dec 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415273,"accession_number":"0001104659-21-148566","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2021-12-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Journey Medical Q3 2021 net revenue $19.6M (+108% YoY); non-GAAP net income $3.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $19.6M vs $9.4M in Q3 2020, up 108%.","Non-GAAP net income $3.5M ($0.38 basic EPS) vs $0.6M in Q3 2020.","Completed November IPO: 3.52M shares at $10, net proceeds $31.2M.","New CFO appointed; DFD-29 Phase 3 first dosing expected Q1 2022.","Cash and equivalents $21.7M as of Sep 30, 2021, up from $8.2M at Dec 31, 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415272,"accession_number":"0001104659-21-138260","cik":1867066,"company_name":"Journey Medical Corp","ticker":"DERM","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["1.01","5.03","9.01"],"status":"ready","headline":"Journey Medical prices underwritten public offering of 3.52M shares at $10.00/share for $35.2M gross proceeds","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Underwriting agreement with B. Riley Securities for 3,520,000 shares of common stock at $10.00 per share.","Gross proceeds expected to be $35.2 million, before underwriting discounts and commissions.","Closing expected on or about November 16, 2021, subject to customary conditions.","Also filed Third Amended and Restated Certificate of Incorporation on November 16, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166033316.86978298,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}